Enzalutamide with standard first-line therapy in metastatic prostate cancer

Ian D. Davis*, Andrew J. Martin, Martin R. Stockler, Stephen Begbie, Kim N. Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E. Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy Parulekar, David W. Pook & 14 others M. Neil Reaume, Shahneen K. Sandhu, Alvin Tan, T. Hsiang Tan, Alastair Thomson, Emily Tu, Francisco Vera-Badillo, Scott G. Williams, Sonia Yip, Alison Y. Zhang, Robert R. Zielinski, Christopher J. Sweeney, ENZAMET Trial Investigators, The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP)

*Corresponding author for this work

Research output: Contribution to journalArticle

179 Citations (Scopus)

Fingerprint Dive into the research topics of 'Enzalutamide with standard first-line therapy in metastatic prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences